Science & Programs
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
The world leader in a new class of drugs designed to regulate disease-associated epigenetics.
BETonMACE – a global Phase 3 clinical trial with the most advanced epigenetic drug outside of oncology.
Providing novel science, clinical and value-based health solutions to key stakeholders, including payer groups.
Resverlogix (TSX: RVX), founded in 2001 by Donald McCaffrey and Norman Wong, focuses on the development of therapeutics for disease states with high unmet medical need.
- : Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
- : Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress
- : Resverlogix Announces Corporate Update Conference Call & Webcast on June 10, 2020 and Upcoming Presentation at the 57th ERA-EDTA Virtual Congress on June 9, 2020